Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

As The World Turns: Cash Raised In France Could Get Vaccines Developed In Cuba Marketed In Asia

This article was originally published in The Pink Sheet Daily

Executive Summary

Abivax’s record-breaking IPO will support development of a therapeutic vaccine against hepatitis B and an antiviral against HIV/AIDS, and the distribution of a series of Cuba-marketed vaccines in Asia.

Advertisement

Related Content

France's Adocia Completes 2012's First Euro Biotech IPO

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS078627

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel